News

STMicroelectronics Set to Reveal Key Q1 2025 Financials Soon

STMicroelectronics Set to Reveal Key Q1 2025 Financials Soon

STMicroelectronics Prepares for Q1 2025 Earnings Release

STMicroelectronics (NYSE: STM) has announced its earnings release schedule for the first quarter of 2025, marking a significant occasion for stakeholders and analysts. Understanding the financial results of a leading global semiconductor firm is crucial for investors and market watchers.

Conference Call Scheduled for Financial Insights

On April 24, 2025, prior to the stock exchanges opening in Europe, STMicroelectronics plans to share its financial results. The company will host a conference call at 9:30 a.m. Central European Time (CET), which will also offer insights into the company's current business outlook. This call promises to be an essential event for those keen to acquire a deeper understanding of STM's financial health and strategic direction.

Accessing the Webcast

For those unable to join the call, a live webcast in listen-only mode will be accessible via the STMicroelectronics investor portal. Additionally, the webcast will be available for replay until May 9, 2025, allowing for convenient access to the information shared during the call.

About STMicroelectronics

As a prominent player in the semiconductor industry, STMicroelectronics empowers a diverse range of electronics applications. With a workforce of over 50,000 skilled individuals, the company has continually pushed the boundaries of technology through state-of-the-art manufacturing facilities and innovative design. Their partnerships with more than 200,000 customers reflect their commitment to solving complex challenges across numerous sectors.

Driving Innovation and Sustainability

The company's dedication to enhancing sustainability is evident in their ambitious goals. STMicroelectronics aims for carbon neutrality in direct and indirect emissions by a set date, alongside a target of sourcing 100% renewable electricity by the end of the decade. Their technologies not only pave the way for smarter mobility but also facilitate more efficient power management and cloud-connected systems.

Investor and Media Relations Contact Information

For investors seeking detailed financial data or specific inquiries, Jérôme Ramel, the EVP of Corporate Development & Integrated External Communication, is available at +41.22.929.59.20. He can provide in-depth insights regarding ST’s financial outlook and strategic initiatives. For media-related questions, Alexis Breton of Corporate External Communications can be reached at +33.6.59.16.79.08 for communications and news developments pertaining to the company.

Frequently Asked Questions

When will STMicroelectronics release its Q1 2025 earnings?

The earnings will be released on April 24, 2025, before the European markets open.

How can I access the conference call?

The conference call can be accessed via STMicroelectronics' investor website, with a live webcast available.

Will there be a replay of the conference call?

Yes, the conference call will be available for replay until May 9, 2025.

What initiatives is STMicroelectronics taking for sustainability?

STMicroelectronics targets carbon neutrality in all its operations and aims for 100% renewable electricity usage by 2027.

Who can I contact for investor inquiries?

Jérôme Ramel is the contact for investor inquiries and can be reached at +41.22.929.59.20.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Photocure Navigates AssureMDx's Medicare Journey

Updated Category News Views 21

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 124

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

Updated Category News Views 14

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 510

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 7

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading
Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 87

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 370

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
AI Agents Redefine Finance: Deutsche & Ant Tech

Updated Category News Views 16

AI Agents: Shaping the Future of Finance The finance world has always been about numbers and precision, but now, with the advent of AI, it’s entering a domain where machines could call the shots. Hold your horses before you imagine free-wheeling robots in suits; this is still the finance sector, where control and audits are holy grails. Deutsche Bank and Ant's Ambitious...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 490

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

First Savings Financial Group Shares Exciting Dividend News

Updated Category News Views 159

First Savings Financial Group, Inc. Declares Special Cash Dividend In a recent announcement, First Savings Financial Group, Inc. (NASDAQ: FSFG), a prominent holding company, revealed that their Board of Directors has approved a quarterly cash dividend of $0.16 per common share. This generous dividend is a reflection of the company’s positive financial health and...

Continue Reading
Ransomware Attacks Surge: Insights from Coalition's Findings

Updated Category News Views 222

Ransomware Attacks Surge: Insights from Coalition's Findings SAN FRANCISCO-- Coalition, the world's first Active Insurance provider designed to prevent digital risk before it strikes, has published its latest findings revealing a significant turnaround in the landscape of cyber threats. Recent statistics show that ransomware claims severity has increased by 68%, reaching...

Continue Reading
Metropolitan Commercial Bank's ACH Cloud Shift: Game Changer or Risky Play?

Updated Category News Views 250

On February 17, 2026, Metropolitan Commercial Bank (MCB) completed a major transition by fully retiring its legacy ACH mainframe and moving to Finzly’s cloud-native payment platform. This move positions MCB as a pioneer among U. S. banks as the industry grapples with modernizing aging systems—a reality that has been highlighted by looming regulatory changes. You know...

Continue Reading
GEODIS Names Laura Ritchey President & CEO of Americas Region

Updated Category News Views 401

GEODIS Appoints New President and CEO for the Americas GEODIS, a prominent figure in the logistics and transportation industry, has announced the appointment of Laura Ritchey to the position of President & CEO of its Americas region. In this crucial role, Ritchey will be part of the Group's Executive Board and will report to Marie-Christine Lombard, the Group's Chief...

Continue Reading
Conagra Brands Set to Share Fiscal 2026 Q2 Earnings Announcement

Updated Category News Views 341

Conagra Brands Announces Earnings Release Date Conagra Brands, Inc. (NYSE: CAG) recently made a significant announcement regarding its fiscal 2026 second quarter results. The much-anticipated earnings release is scheduled for a Friday, marking an important milestone for the company and its stakeholders. Details of the Earnings Call The earnings call will take place on a...

Continue Reading